When Aardvark Therapeutics announced earlier this month that it was pausing a phase 3 trial of its lead metabolic candidate, ...

Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its ...

Sanofi has returned to T-cell engager (TCE) territory via an agreement to pay $180 million in the near term for a phase 1-stage trispecific antibody from Kali Therapeutics. The California biotech took ...

Qatar’s exports of natural gas and helium—the latter essential for MRI scans—were effectively halted after Iran closed the Strait of Hormuz and attacked one of the world’s largest production ...

Last year’s funding cuts at the National Institutes of Health (NIH) disproportionately impacted women and early-career researchers, according to a new analysis, raising questions about what the future ...

Apogee Therapeutics has published phase 2 eczema data that suggest its anti-IL-13 antibody is a threat to Eli Lilly, Regeneron and Sanofi, prompting analysts to double their peak sales forecast to $5.

Stryker continues to dig itself out of the hole left by the global cyberattack it suffered nearly two weeks ago, saying its medical device manufacturing capacity is “ramping quickly as cr | Stryker ...

When Ron Cohen, M.D., CEO of Oryon Cell Therapies, recently dug into the company’s Parkinson’s disease data, he told Fierce Biotech it “sang” to him. | When Ron Cohen, M.D., CEO of Oryon Cell ...

In this episode of The Top Line, Olive McCormick joins host Chris Hayden to examine one of the most overlooked risks in ...

Health authorities in the U.S. are continuing their move away from animal testing in drug development, with the FDA signaling ...

Swiss pharma Roche is staying in lockstep with Eli Lilly, expanding its artificial intelligence offerings and Nvidia ...

Gilead has handed back a next-gen hepatitis B antiviral to Assembly Biosciences, while the two companies continue to partner ...